Industry
Biotechnology
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Loading...
Open
30.41
Mkt cap
2.5B
Volume
478K
High
30.60
P/E Ratio
-12.87
52-wk high
47.73
Low
29.80
Div yield
N/A
52-wk low
27.52
Portfolio Pulse from
November 07, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 29, 2024 | 3:38 pm
Portfolio Pulse from Suganya Shanmugam
October 28, 2024 | 10:02 am
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 12:02 pm
Portfolio Pulse from Nabaparna Bhattacharya
October 25, 2024 | 10:04 am
Portfolio Pulse from Benzinga Newsdesk
October 24, 2024 | 11:34 am
Portfolio Pulse from Nabaparna Bhattacharya
October 04, 2024 | 10:05 am
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 5:37 pm
Portfolio Pulse from Benzinga Newsdesk
September 24, 2024 | 12:41 pm
Portfolio Pulse from Vandana Singh
September 23, 2024 | 2:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.